Side-by-side · Research reference
EpitalonvsHexarelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/37 cited
BPhase 1Reviewed19/45 cited
Epitalon
Pineal bioregulator · Telomerase activator
SQ or IM · Abdomen · Daily for 10–20 days
Hexarelin
Hexapeptide GHRP · Cardio-tropic
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
Epitalon
Hexarelin
Primary target
Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003
Ghrelin receptor (GHS-R1a) + cardiac CD36Smith 1996Ghigo 1997
Pathway
Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003
GHS-R1a → Gαq → Ca²⁺ → GH release. CD36 engagement → direct cardio-tropic actionGhigo 1997
Downstream effect
Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003
Strong GH pulse + IGF-1 elevation; cardio-protective effects in animal MI modelsGhigo 1997
Origin
Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003
Synthetic hexapeptide His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂Smith 1996
Antibody development
—
—
02Dosage Protocols
Parameter
Epitalon
Hexarelin
Standard dose
5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003
Anecdotal community protocol. Russian clinical literature uses similar cycling.
100–200 mcg per injectionSmith 1996
Frequency
Once daily during a cycle
1–2× per day max (tachyphylaxis with chronic 3× daily)
Lower / starter dose
2.5 mg / day
50 mcg per dose
Evidence basis
In-vitro telomerase + Russian clinical trialsKhavinson 2003
Phase 1 / Phase 2 trialsSmith 1996Ghigo 1997
Duration
10–20 day cycles, 1–2× per year
4–8 weeks on / 4–8 weeks off (tachyphylaxis mitigation)
Reconstitution
Bacteriostatic water
Bacteriostatic water
Timing
Pre-sleep preferred (pineal alignment)
Pre-sleep + fasted preferred
04Side Effects & Safety
Parameter
Epitalon
Hexarelin
Injection site reaction
Mild irritation
—
Sleep architecture
Improved subjective sleep quality (anecdotal)
—
Cancer risk
Theoretical via telomerase activation in pre-malignant cells
Contraindicated in active malignancy (GH/IGF-1 axis)
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid
Avoid
Antibody formation
Not reported
—
Hunger
—
Strong appetite increase via ghrelin agonism
IGF-1 elevation
—
Strong; monitor with chronic high-dose use
Absolute Contraindications
Epitalon
- ·Pregnancy / breastfeeding
- ·Active malignancy or pre-malignant state
Hexarelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
Epitalon
- ·Family history of cancer
Hexarelin
- ·Untreated diabetes
- ·Severe hyperprolactinemia
05Administration Protocol
Parameter
Epitalon
Hexarelin
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Injection site
SQ — abdomen preferred. Rotate sites.
SQ — abdomen or thigh. Rotate sites.
3. Timing
Pre-sleep preferred to align with pineal axis.
Pre-sleep + fasted preferred. Cycle on/off to avoid tachyphylaxis.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Epitalon
— no documented stacks
Hexarelin
+ CJC-1295 (no DAC)
StrongHexarelin (GHRP) + CJC-1295-no-DAC (GHRH analogue) is the higher-amplitude variant of the standard GHRH+GHRP stack. Hexarelin produces a stronger pulse than ipamorelin but with cortisol + prolactin signal — choose this stack for maximum GH amplitude when side-effect tolerance is acceptable. Cycle aggressively.
- Hexarelin
- 100 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Maximum GH pulse amplitude (with side-effect signal)